Prime Securities Launches ₹1,000 Crore Fund to Target High-Yield Real Estate Debt
Source: Economictimes
Arth Insight · What this means for your wallet
- This fund offers structured credit to real estate developers, not direct property ownership for you.
- It aims for high returns (18-20% IRR) but comes with high risks, suitable only for very wealthy investors.
- For the average Indian, this news signals that big money is flowing into real estate, potentially stabilizing or increasing property values in major cities.
Prime Litmus Investment Management has introduced a new Category II Alternative Investment Fund aimed at under-construction residential projects. The fund seeks to raise up to ₹1,000 crore by offering structured credit to developers in India’s top metropolitan cities.
- ▸The fund acts as a lender to developers of under-construction projects in major Indian cities.
- ▸It aims for high returns of 18-20% over a six-year period through structured debt.
- ▸The total fund size could reach ₹1,000 crore including the green shoe option.
- ▸It offers a regulated avenue for wealthy investors to gain exposure to real estate credit.
- ✓The fund acts as a lender to developers of under-construction projects in major Indian cities.
- ✓It aims for high returns of 18-20% over a six-year period through structured debt.
- ✓The total fund size could reach ₹1,000 crore including the green shoe option.
- ✓It offers a regulated avenue for wealthy investors to gain exposure to real estate credit.
Prime Securities, through its investment arm Prime Litmus Investment Management, has announced the launch of the 'Prime Litmus Real Estate Opportunities Fund.' This new Category II Alternative Investment Fund (AIF) is designed to tap into the credit requirements of India’s rebounding real estate sector, offering high-net-worth individuals a structured way to participate in property debt.
Fund Size and Growth Strategy
The fund has set a base target of ₹750 crore, with an additional 'green shoe' option of ₹250 crore, bringing the total potential corpus to ₹1,000 crore. Unlike traditional equity funds that buy into property ownership, this fund focuses on structured credit. This means it lends money to developers, securing the investment against the project's cash flows and assets.
The management team is targeting an Internal Rate of Return (IRR) in the range of 18% to 20%. The fund has a designated tenure of six years, aligning with the typical lifecycle of mid-to-large scale residential developments.
Focus on Metropolitan Markets
The Prime Litmus Real Estate Opportunities Fund will concentrate its capital on under-construction projects located in India’s primary metropolitan regions. These areas often face a 'credit gap' where developers require flexible funding that traditional banks may not provide due to regulatory constraints on land or early-stage construction financing.
Investment Structure and Benefits
By operating as a Category II AIF, the fund provides a regulated vehicle for sophisticated investors to earn higher yields than those typically found in standard fixed-income products. The core strategy involves:
- Structured Credit: Providing customized loans to developers with clear exit timelines.
- Under-Construction Projects: Focusing on the high-growth phase of real estate where capital demand is peak.
- Risk Management: Diversifying across multiple projects in key growth corridors to mitigate localized market risks.
The launch comes at a time when the Indian real estate market is seeing a resurgence in demand for residential units, particularly in the premium and mid-income segments. By bridging the funding gap for developers, Prime Litmus aims to capture high interest margins while ensuring the underlying projects have the necessary liquidity to reach completion.
Investment in Alternative Investment Funds involves high risk; please consult with a financial advisor and read all fund-related documents carefully before investing.
Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about real-estate
From Chartered Accountant to Fitness Guru: Dinaz Vervatwala's Wellness Journey
Dinaz Vervatwala, founder of Hyderabad's Dinaz's Fitness, transitioned from a chartered accountant to a prominent fitness and wellness coach. Her journey emphasizes holistic wellness, integrating mental health and sustainable practices, inspired by overcoming a personal accident.
Zydus Lifesciences Finalises 50% Joint Venture with Sunshine Healthcare Lanka
Zydus Lifesciences Ltd. has completed its 50:50 joint venture transaction with Sunshine Healthcare Lanka Limited, securing a 50% interest in Zydus Sunshine Lifesciences Pvt Ltd. The partnership was finalised on November 11, 2026, following an extension from its original June 2026 closing date. This strategic move aims to expand Zydus's presence through collaboration.
CCI Clears Advent International's ₹3,150 Crore Investment in Yatharth Hospitals
The Competition Commission of India (CCI) has approved Advent International's substantial ₹3,150 crore investment in Yatharth Hospitals through its affiliate, Rasmalai Limited. This deal will grant Advent a 24.9% minority stake in the healthcare provider. Yatharth Hospitals plans to utilize these funds for its expansion efforts and to enhance its healthcare network, buoyed by strong operational revenues and profit growth.
Related Stories
From Chartered Accountant to Fitness Guru: Dinaz Vervatwala's Wellness Journey
Dinaz Vervatwala, founder of Hyderabad's Dinaz's Fitness, transitioned from a chartered accountant to a prominent fitness and wellness coach. Her journey emphasizes holistic wellness, integrating mental health and sustainable practices, inspired by overcoming a personal accident.
Zydus Lifesciences Finalises 50% Joint Venture with Sunshine Healthcare Lanka
Zydus Lifesciences Ltd. has completed its 50:50 joint venture transaction with Sunshine Healthcare Lanka Limited, securing a 50% interest in Zydus Sunshine Lifesciences Pvt Ltd. The partnership was finalised on November 11, 2026, following an extension from its original June 2026 closing date. This strategic move aims to expand Zydus's presence through collaboration.
CCI Clears Advent International's ₹3,150 Crore Investment in Yatharth Hospitals
The Competition Commission of India (CCI) has approved Advent International's substantial ₹3,150 crore investment in Yatharth Hospitals through its affiliate, Rasmalai Limited. This deal will grant Advent a 24.9% minority stake in the healthcare provider. Yatharth Hospitals plans to utilize these funds for its expansion efforts and to enhance its healthcare network, buoyed by strong operational revenues and profit growth.
BreakingPiramal Pharma Slashes China Reliance to Under 10% for Supply Chain Resilience
Piramal Pharma has significantly reduced its dependence on Chinese raw materials to less than 10%. This strategic move aims to enhance supply chain resilience against geopolitical risks, with the company expanding its manufacturing footprint to India, the UK, and the US.